HSX Holdings

HSX Holdings S.A. is the parent holding company for the Helsinn Group, a privately held Swiss pharmaceutical company dedicated to improving the lives of cancer patients through innovative supportive care and targeted therapies. Founded in 1976, the group operates an integrated business model that spans early-stage research and development, high-potency API manufacturing, and global commercialization. Its market-leading portfolio is anchored by products such as Akynzeo and Aloxi, which address chemotherapy-induced nausea and vomiting (CINV). Beyond supportive care, Helsinn has expanded into cancer therapeutics with assets like Truseltiq for cholangiocarcinoma and Valchlor for cutaneous T-cell lymphoma. The company maintains a significant international presence with key operations in Switzerland, Ireland, and the United States, and continues to invest in early-stage biotech innovation through the Helsinn Investment Fund.